Tag: <span>aav</span>

From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce

There are so many exciting things happening in the biotech industry. As we have all seen, antibody products are being approved for more and more cancer applications, in addition to those for auto-immune diseases, which used to dominate how they were being used. And of course, these applications are in addition to the many which use antibodies conjugated to chemotherapeutic drugs and imaging agents—where the antibody acts as a targeting mechanism. Then there are the hundreds of monoclonal and polyclonal antibody applications that have dominated diagnostic testing for decades…

Read MoreFrom the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce

Biologics Production

aav adeno-associated virus air handling antibody conjugates biologics bioproduction cryopreservation diagnostic testing ind investigational new drug lentiviral vector systems monoclonal antibodies polyclonal antibodies regenerative tissues subunit vaccines transient transfection viral gene vectors

From the Editor-in-Chief: A “Renaissance” of Sorts Within the Biologics Industry

We just completed our 6th ISBioTech Spring Meeting, and it was a resounding success. And while the attendee numbers were up considerably, the more important aspects for me were that we had the “right” people, plus incredibly valuable content. Then what impressed me the most was the happiness and hopefulness I saw during the meals, receptions, and the banquet. We’ve been organizing these meetings for over 20 years, and I haven’t experienced anything like this since our earliest days in Williamsburg…

Read MoreFrom the Editor-in-Chief: A “Renaissance” of Sorts Within the Biologics Industry

Biologics Production

aav adeno-associated virus baculovirus expression technology biologics bioproduction car t-cells chimeric antigen-receptor expression systems hpv vaccine internal reference materials mab monoclonal antibodies rhabdovirus sf9 cells therapeutic cancer vaccines vaccine development vaccines

From the Editor-in-Chief: Good News! The Licensure of Biologics is Really Taking Off

The licensure of biologics is really taking off as we all hoped it would in the ‘90s. There are a number of key factors including the advanced ability to produce adeno-associated virus (AAV) with baculovirus expression technology (BET), as well as the ability of BET to produce antigens that can successfully be used as vaccines. Then of course, there is the first licensed human gene therapy from uniQure, which is based on AAV-1 that was derived from BET…

Read MoreFrom the Editor-in-Chief: Good News! The Licensure of Biologics is Really Taking Off

Biologics Production

aav aav gene therapies adeno-associated virus baculovirus expression technology bet biologics bioproduction conjugated antibodies FDA internal reference assays internal reference materials lentiviral vectors lentivirus